X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

How Patients With Metastatic Prostate Cancer Can Be Informed By Biomarker Testing

One out of every nine men—that’s how many will be diagnosed with prostate cancer in their lifetime. Most of those cases will be low risk—involving tumors that grow slowly and aren’t very aggressive. But in 10 to 20 percent of cases, within ~5 years of follow-up, the cancer develops into castration-resistant prostate cancer. This means that the tumors may not react to standard hormone therapy and, for at least 84 percent of patients, metastasize within five years of diagnosis, meaning the tumors spread to other areas like bones, organs, and lymph nodes.

Read the full article here.

source: Alice Oglethorpe - Men's Health